Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Vincent D de Jager, Jos A Stigt, Maarten Niemantsverdriet, Arja Ter Elst, Anthonie J van der Wekken

    OnderzoeksoutputAcademicpeer review

    9 Downloads (Pure)

    Samenvatting

    Precision cancer medicine has changed the treatment paradigm of patients with non-small cell lung cancer (NSCLC) with specific molecular aberrations. A major challenge is management of the resistance that tumor cells eventually develop against targeted therapies, either through primary or acquired resistance mechanisms. We report a 61 year-old male patient with metastatic NSCLC harboring an EGFR exon 19 deletion, a PIK3CA mutation, and CDK4 amplification. After an initial partial response to osimertinib as mono-therapy (third-generation EGFR tyrosine kinase inhibitor), the patient had progression of disease after 4 months of treatment and was referred for combined osimertinib and palbociclib (CDK4/6 inhibitor) treatment. Though complicated by transient pneumonitis, the patient has an ongoing partial response for > 10 months and has experienced clinical improvement on this treatment regimen. As amplification of CDK4 occurs in ~ 10% of treatment-naïve patients with EGFR-mutated NSCLC, the successful treatment of our patient with osimertinib and palbociclib may be highly relevant for future patients with NSCLC.

    Originele taal-2English
    Artikelnummer113
    Aantal pagina's4
    TijdschriftNPJ precision oncology
    Volume8
    Nummer van het tijdschrift1
    DOI's
    StatusPublished - 22-mei-2024

    Vingerafdruk

    Duik in de onderzoeksthema's van 'Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit